HCA Healthcare delivered strong revenue, earnings, and cash flow growth despite a choppy quarter. The stock looks attractively valued, but its heavy debt load keeps the risk profile elevated.
HCA Healthcare (HCA) looks like a high-quality operator wrapped in a balance sheet that demands respect. The bullish case starts with scale, cash generation, and execution. HCA generated $75.60B of revenue and $6.78B of net income in 2025, with operating cash flow of $12.64B and free cash flow of $7.69B. In Q1 2026, revenue rose 4.3% to $19.109B, diluted EPS increased 10.9% to $7.15, adjusted EBITDA reached $3.802B, and operating cash flow climbed 22% to $2.014B. Those are not the numbers of a fragile hospital chain.
The more interesting part is that HCA produced those results during a quarter management described as unusually choppy. Respiratory-related admissions fell 42%, respiratory-related ER visits fell 32%, and a January winter storm reduced admissions and ER visits across markets including Texas, Tennessee, North Carolina, and Virginia. CFO Mike Marks said those two factors cut Q1 adjusted EBITDA by an estimated $180M. Even so, HCA kept full-year 2026 guidance unchanged at $76.5B to $80.0B of revenue, $15.55B to $16.45B of adjusted EBITDA, and $29.10 to $31.50 of diluted EPS. That says something important: the operating machine still works when the road gets slick.
The bear case is also plain enough. HCA ended 2025 with $48.70B of total debt, just $1.04B of cash, net debt of about $47.66B, a current ratio of 0.83, and negative book value per share of -$28.324. The company can carry that leverage because the business throws off large cash flow, but it narrows the margin for error if reimbursement shifts, uninsured volumes rise, or policy support around Medicaid supplemental payments weakens.
For a balanced, moderate-risk investor with a medium-term horizon, HCA fits best as a selective Buy rather than a blind one. The stock trades at 12.5x trailing earnings, 12.9x forward earnings, and a PEG ratio of 1.18. Those are not demanding multiples for a company with HCA’s market position and earnings history, including beats in 6 of the last 7 reported quarters. The setup is attractive because the market is pricing in real policy and payer risk, but not enough to erase the company’s scale advantage, pricing power by market density, and disciplined capital allocation.
HCA Healthcare is a large U.S.-focused health care facilities operator headquartered in Nashville, Tennessee. The company was founded in 1968, trades on the NYSE under HCA, and employs about 230,000 people. Its business spans hospitals, ambulatory surgery centers, freestanding emergency rooms, urgent care, walk-in clinics, imaging centers, oncology and rehab facilities, physician practices, home health agencies, hospices, and other care settings.
As of the latest business context, HCA operated 186 hospitals and about 2,400 ambulatory sites of care across 20 states and the U.K. A separate company profile reference in the industry context lists 190 hospitals at December 31, 2025, including 179 general acute care, 7 behavioral, and 4 rehabilitation hospitals. Either way, the core point is unchanged: HCA is the scale leader among for-profit hospital operators in the U.S., and scale is not a cosmetic advantage in this business. It affects purchasing, staffing flexibility, payer negotiations, technology rollout, and local referral density.
Financially, HCA sits in the sweet spot that often defines strong service franchises. Revenue has risen from $58.75B in 2021 to $75.60B in 2025. Gross margin improved from 38.3% to 41.5% over that span, while operating income increased from $9.68B to $11.96B. Net income dipped in 2022 and 2023 before recovering to $6.78B in 2025, which shows the business is not immune to cost and reimbursement pressure, but it also shows the company can rebuild earnings power.
The stock’s market capitalization is about $80.66B. That puts HCA in a large-cap bracket where investors expect stability, not excuses. So far, the company has largely delivered on that standard.
HCA’s reported revenue mix is best understood through payer categories rather than neat product silos. For 2025, total revenue in the segment dataset was $73.142B. Managed Care and Other Insurers contributed $36.968B, or 50.5% of total. Managed Medicare added $13.435B, or 18.4%. Medicare contributed $11.273B, or 15.4%. Medicaid contributed $5.909B, or 8.1%. Managed Medicaid contributed $3.693B, or 5.0%. International revenue was $1.864B, or 2.5%.
That mix matters because it shows where HCA’s earnings engine really lives. Commercial and managed care remain the anchor, with just over half of revenue. Those patients typically carry better reimbursement economics than government programs. It also means HCA’s profitability depends heavily on employer coverage trends, exchange behavior, and payer contract discipline. When CFO Mike Marks said commercial equivalent admissions excluding exchanges increased 0.6% in Q1 2026, that was a small number with big importance.
Government-linked revenue is still massive. Combining Managed Medicare, Medicare, Managed Medicaid, and Medicaid produces more than $34B of 2025 revenue in the segment data. That gives HCA scale and demand resilience, but it also exposes the company to reimbursement formulas, supplemental payment programs, and policy changes that can shift economics quickly. In Q1 2026, Marks said HCA realized an increase in net benefits of about $200M to adjusted EBITDA from Medicaid supplemental programs versus the prior quarter, driven by Georgia, Texas, and Tennessee program effects.
International is small at 2.5% of revenue, so HCA is overwhelmingly a U.S. reimbursement story. That simplifies the operating model but concentrates policy risk. There is no geographic diversification shield here if U.S. payer dynamics turn hostile.
Operationally, HCA also reports same-facility metrics that cut across the network. In Q1 2026, same-facility admissions rose 0.9%, equivalent admissions rose 1.3%, ER visits rose 0.3%, inpatient surgeries fell 0.3%, and outpatient surgeries fell 1.7%. Same-facility revenue per equivalent admission increased 3.1%. That mix says HCA is still finding revenue growth through acuity and pricing even when procedure volumes wobble.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
HCA does not have a flagship product in the way a device or software company does. Its flagship asset is the acute-care hospital network, supported by ambulatory and emergency access points that feed volume into the broader system. In plain English, the hospital is still the engine, and the outpatient network is the transmission.
The best evidence is in management’s own operating commentary. In Q1 2026, HCA said its networks expanded overall sites of care by more than 4%, increased hospital beds through capital spending by almost 1%, and added 4% to emergency room capacity versus the prior year. That combination shows where capital is going: more local access, more capacity, and tighter network density.
The hospital platform also remains the main earnings driver because modest volume changes move a large fixed-cost base. Marks said the respiratory shortfall and winter storm reduced adjusted EBITDA by an estimated $180M in Q1. That is the downside of hospital economics. The upside is the same mechanism in reverse. When volumes normalize, operating leverage returns quickly.
Outpatient and ambulatory assets matter because they help HCA keep patients inside its system as care shifts away from traditional inpatient settings. The company’s description includes ASCs, urgent care, imaging, physician practices, rehab, home health, and hospice. That broad site-of-care footprint is less glamorous than a new drug launch, but strategically it is exactly what a hospital operator needs. It protects referrals, captures lower-acuity demand, and reduces the risk of becoming a stranded inpatient asset.
HCA’s moat is built from scale, local density, and process discipline. The company’s own business context points to economies of scale in medical supplies and administrative services. That sounds dry, but in hospitals, dry is good. Savings on labor workflows, supplies, and denials management compound across a network this large.
Management has also been explicit that AI and digital workflow are no longer side projects. CEO Sam Hazen said the digital transformation program and AI agenda progressed during Q1 2026 with rollout of key initiatives to more facilities. He cited ambient listening capabilities for physicians, documentation productivity, nurse handoff programs, and case management improvements that contributed to reductions in average length of stay.
That matters because HCA does not need AI to invent a new market. It needs AI to shave friction from a huge existing one. A few basis points of labor efficiency, documentation improvement, or throughput gain across this network can move real money. Hazen also tied the broader resiliency plan to cost savings, network execution, and stronger organizational capabilities. In a hospital system, innovation is less about moonshots and more about making the machine run cleaner.
Another competitive advantage is HCA’s ability to absorb shocks without rewriting the playbook every quarter. In Q1 2026, respiratory-related admissions fell 42% and ER visits fell 32%, yet revenue still rose 4.3% and EPS still rose 10.9%. That does not mean the business is immune. It means HCA has enough pricing power, reimbursement tools, and cost discipline to keep the income statement from unraveling when one volume lane weakens.
The company is also investing heavily enough to defend its position. Q1 2026 capital expenditures were $1.119B, and full-year 2026 capex guidance is $5.0B to $5.5B. Smaller operators often talk about modernization. HCA writes checks.
HCA’s operations story in early 2026 was a study in resilience under uneven demand. Same-facility admissions rose 0.9% and equivalent admissions rose 1.3%, but inpatient surgeries fell 0.3% and outpatient surgeries fell 1.7%. ER visits increased just 0.3%. Those are hardly booming volume numbers, and management tied the softness to a milder respiratory season and a January winter storm.
Marks quantified the hit with unusual clarity. Respiratory and weather effects reduced quarterly volume growth in admissions and ER visits by 70 basis points and 140 basis points, respectively. The storm alone reduced admissions and ER visits by an estimated 30 basis points and 50 basis points. Together, those factors cut adjusted EBITDA by about $180M. Investors rarely get a cleaner bridge than that.
The cost side was mixed but manageable. In Q1 2026, salaries and benefits as a percentage of revenue improved 30 basis points, and supplies improved 20 basis points. Other operating expenses as a percentage of revenue increased 90 basis points, primarily due to costs related to Medicaid state supplemental payments, professional fees, and technology investments. That is a fair trade if the technology spend produces durable productivity gains.
Cash generation remained solid. Q1 operating cash flow was $2.014B, up 22% from $1.651B a year earlier, while capital expenditures were about $1.1B. For 2025, operating cash flow reached $12.64B and capex was $4.94B. That annual capex burden is large, but HCA still produced $7.69B of free cash flow in the annual statements. In a capital-intensive industry, that is a sign of operating strength.
Supply chain detail is limited in the dataset, but HCA’s scale and centralized purchasing are part of its stated model. The company’s gross margin improved from 38.3% in 2021 to 41.5% in 2025, which supports the view that procurement discipline and operating standardization are doing real work, not just filling slides.
HCA operates inside a large, steady-demand market with a structural shift in how care is delivered. Industry context highlights continued migration toward outpatient, ambulatory, urgent care, and home-based settings. That shift can pressure inpatient growth, but it favors operators that already own a broad care continuum. HCA does.
The company’s opportunity is not limited to hospital beds. Its platform includes hospitals, ambulatory surgery centers, freestanding ERs, urgent care, physician clinics, imaging, rehab, home health, and hospice. That matters because the market is rewarding systems that can keep patients in-network across settings rather than defending a single building type.
Demand drivers remain durable. Industry context points to an aging population, chronic disease burden, and continued healthcare infrastructure investment. At the same time, digital and smart-hospital layers are growing faster than the broader facilities market. HCA’s AI and workflow investments fit that trend well because they target throughput, documentation, and care coordination rather than speculative tech theater.
Near-term growth for HCA still comes from familiar levers. In Q1 2026, same-facility revenue per equivalent admission rose 3.1%, while same-facility equivalent admissions rose 1.3%. That combination supports revenue growth even in a quarter with weak respiratory demand. Over the medium term, analyst estimates project revenue rising from about $82.26B in 2027 to $97.96B in 2030, while EPS is projected to increase from $33.21 to $48.73.
That is not hypergrowth. It is something better for this sector: visible compounding in a market with stubborn demand. Hospitals are rarely exciting. They are often essential, and essential can be lucrative when the operator is disciplined.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
HCA’s customer base is broad, but the revenue mix shows who pays the bills. In 2025, Managed Care and Other Insurers represented 50.5% of revenue, making commercially insured patients the economic core of the business. Managed Medicare and traditional Medicare together represented 33.8%, while Medicaid and Managed Medicaid represented 13.1%. International was 2.5%.
This mix creates a business that is diversified by payer but still highly sensitive to reimbursement quality. Commercial patients support margins. Medicare provides scale and demand. Medicaid and exchange-related populations create both volume and collection complexity. Marks said same-facility exchange equivalent adjusted admissions declined about 15% in Q1 2026, while same-facility uninsured equivalent admissions increased about 16% versus the prior year quarter. He estimated the exchange impact on adjusted EBITDA at about $150M in Q1 2026.
The customer profile also shows why HCA invests in network breadth. Patients do not experience healthcare as a segment chart. They move from ER to inpatient to rehab to outpatient follow-up. A system that owns more of those handoffs can protect both care continuity and economics.
On the payer side, HCA is also dealing with more aggressive utilization management. Marks said the company continues to experience increased activity levels with payers on denials and underpayments, and specifically called out Medicare Advantage as a driver. That means HCA’s real customer is partly the patient and partly the insurer. In this industry, both can be demanding, and only one sends prior authorization forms at midnight.
HCA competes with public for-profit peers including Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), and Ardent Health (ARDT), along with nonprofit systems, academic medical centers, ambulatory providers, and physician networks. The competition is local, not abstract. Hospitals win or lose market share city by city, physician by physician, and contract by contract.
HCA’s main edge is scale plus density. The business context describes it as the largest for-profit hospital operator in the U.S. by scale. That gives the company more leverage in purchasing, more ability to spread technology investment, and more referral capture across local networks. Its continued expansion in sites of care, beds, and ER capacity reinforces that edge.
The company also has a better financial engine than many smaller peers. HCA produced $15.566B of EBITDA on a trailing basis, $12.64B of operating cash flow in 2025, and $7.69B of free cash flow in the annual statements. That cash supports capex, buybacks, dividends, and selective acquisitions. In Q1 2026 alone, HCA repurchased 3.157M shares for $1.571B and paid $183M in dividends, while still spending $1.1B on capex.
Where HCA is less advantaged is in policy exposure. Its size does not exempt it from payer pressure, Medicaid program volatility, or exchange churn. But scale does improve its odds of adapting faster than smaller operators. Hazen’s comments on resiliency, AI rollout, and network execution support that view.
HCA’s macro exposure is mostly domestic and mostly policy-driven. This is not a company whose earnings swing on foreign exchange or export demand. Its key macro variables are labor inflation, reimbursement policy, insurance coverage shifts, and state and federal healthcare funding.
Management’s 2026 guidance explicitly incorporates volume growth, a mostly stable operating environment, payer mix effects, health insurance exchange impacts from administrative reforms and the expiration of enhanced premium tax credits, resiliency initiatives, inflation, and tariffs. That list is useful because it shows where management itself sees the pressure points.
The biggest macro issue in 2026 is coverage mix. Marks said HCA still believes the full-year exchange impact of $600M to $900M on adjusted EBITDA is appropriate. In Q1 2026, same-facility exchange equivalent adjusted admissions declined about 15%, and uninsured equivalent admissions increased about 16%. He also said the company included increased patient amounts due from exchange plans in its original estimate. That is corporate language for a simple problem: more patients with weaker economics.
Medicaid supplemental programs are another major variable. Q1 2026 got a boost from Georgia, Texas, and Tennessee program effects, and Marks said the only change to key 2026 guidance assumptions related to supplemental payment programs. Florida remains a notable swing factor because management said it feels positive about approval prospects and that the revenue impact, if approved, may be significant. That is upside, but it is policy-shaped upside, which means investors should treat it as a bonus rather than a base case.
Weather also showed up as a real operating factor in Q1. That is not a macro thesis, but it is a reminder that hospitals are physical networks with local exposure. A winter storm can hit volumes before any spreadsheet catches up.
HCA ended 2025 with $48.70B of total debt, just $1.04B of cash, a current ratio of 0.83, and negative book value per share of -$28.324, leaving little room for operational missteps.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue climbed to $75.60B in 2025 and Q1 2026 EPS rose 10.9% to $7.15, while adjusted EBITDA reached $3.802B despite a $180M hit from storms and respiratory volume weakness.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management kept 2026 guidance unchanged at $76.5B-$80.0B of revenue, $15.55B-$16.45B of adjusted EBITDA, and $29.10-$31.50 of diluted EPS after a volatile first quarter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →HCA trades at 12.5x trailing earnings, 12.9x forward earnings, and a PEG ratio of 1.18, which leaves room for upside if execution stays steady.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework points to $470 as fair value, with stronger upside cases extending to $520 and $580 if sentiment and fundamentals improve.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →HCA Healthcare is a classic case of a strong business carrying a balance sheet that keeps investors honest. The company has scale, dense local networks, improving margins, strong cash flow, and a credible record of executing through messy quarters. Q1 2026 was messy by any fair standard, yet HCA still grew revenue 4.3%, increased EPS 10.9%, generated $2.014B of operating cash flow, and reaffirmed full-year guidance.
That does not erase the risks. Total debt near $48B, cash below $1B, a current ratio of 0.83, and exchange-related EBITDA pressure are meaningful constraints. But the stock already reflects a good deal of that discomfort. At around $380, investors are paying a modest multiple for a business that still looks structurally advantaged in its sector.
For moderate-risk investors with a medium-term horizon, HCA earns a Buy. The company is not built for drama, and that is precisely the point. In healthcare facilities, the winners are often the operators that keep the machine running while everyone else argues about the weather. HCA has done that well enough to deserve a premium to panic, if not a premium to perfection.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
HCA’s latest guidance cut turned a policy risk into an earnings problem. When exchange coverage losses are already stripping roughly $400 million from one quarter, the scale-and-efficiency defense stops carrying the stock.
HCA remains a high-quality hospital operator with steady volume growth, improving margins, and aggressive buybacks. Policy headwinds could pressure 2026 earnings, but the business still looks attractive for moderate-risk investors.
HCA Healthcare, Inc. (HCA) drops after Q1 2026 earnings as investors focus on softer patient volumes, weather disruption, and a mixed operating outlook. Revenue and EPS were solid, but the market wants clearer evidence that hospital demand is reaccelerating before rewarding the stock again.